试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-07-15
A Single Center Study to Evaluate Ticagrelor Mechanism of Action in Inhibiting Juvenile Platelet ADP Response
编号:NCT03027934登记状态:入组前撤回企业 / 申办者:CirQuest Labs, LLC
药物 / 成分:Ticagrelor、Prasugrel
登记的停止原因(原文):Study population difficult to recruit
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-07-15
Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells in Subjects With Osteoarthritis
编号:NCT03602872登记状态:入组前撤回企业 / 申办者:Clinica Santa Clarita, Mexico
药物 / 成分:Human allogeneic mesenchymal bone marrow derived stem cells
登记的停止原因(原文):Sponsor to start with different protocol, postponed due to COVID
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-07-15
Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer
编号:NCT04272645登记状态:入组前撤回企业 / 申办者:University of Michigan Rogel Cancer Center
药物 / 成分:Abemaciclib 200 MG、Atezolizumab 1200 MG in 20 ML Injection、Abemaciclib 150 MG
登记的停止原因(原文):Coordinating site change
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-07-15
Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease.
编号:NCT04293172登记状态:入组前撤回企业 / 申办者:AstraZeneca
药物 / 成分:Brilinta、Placebo
登记的停止原因(原文):Study halted prematurely, prior to enrolment of first patient.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-07-15
E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia
编号:NCT04411134登记状态:入组前撤回企业 / 申办者:National Cancer Institute (NCI)
药物 / 成分:E7 TCR
登记的停止原因(原文):Closed based on the lack of perceived clinical activity observed from a different study treating a similar patient population with same study agent.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-07-14
Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia
编号:NCT04106076登记状态:入组前撤回企业 / 申办者:Cellectis S.A.
药物 / 成分:UCART123
登记的停止原因(原文):The trial was discontinued due to sponsor's decision and not a consequence of any safety concern
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-07-13
Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Knee Replacement in Patients With High PCS Scores
编号:NCT03797612登记状态:入组前撤回企业 / 申办者:Adynxx, Inc.
药物 / 成分:Brivoligide Injection 660 mg/6 mL、Placebo 6 mL
登记的停止原因(原文):Study initiation delayed due to COVID 19
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-07-13
Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Mastectomy in Patients With High PCS Scores
编号:NCT04104919登记状态:入组前撤回企业 / 申办者:Adynxx, Inc.
药物 / 成分:Brivoligide Injection 660 mg/6 mL、Placebo 6 mL
登记的停止原因(原文):Study Initiation delayed due to COVID 19
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-07-13
ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia
编号:NCT04256148登记状态:入组前撤回企业 / 申办者:Alexion Pharmaceuticals, Inc.
药物 / 成分:ALXN1830、Placebo
登记的停止原因(原文):Study is withdrawn due to the global impact of the COVID-19 pandemic.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-07-10
Effects and Safety of Infusion of Low-Doses of Methylprednisolone in Early ALI and ARDS in Children
编号:NCT01757899登记状态:入组前撤回企业 / 申办者:Universidade Federal do Rio de Janeiro
药物 / 成分:Methylprednisolone Arm、Sterile Saline Arm
登记的停止原因(原文):Technical problems
查看官方原始记录 ↗